Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Drug Discov Today ; 27(1): 134-150, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34547449

RESUMO

Despite the devastating impact of many lung diseases on human health, there is still a significant unmet medical need in respiratory diseases, for which inhaled delivery represents a crucial strategy. More guidance on how to design and carry out multidisciplinary inhaled projects is needed. When designing inhaled drugs, the medicinal chemist must carefully balance the physicochemical properties of the molecule to achieve optimal target engagement in the lung. Although the medicinal chemistry strategy is unique for each project, and will change depending on multiple factors, such as the disease, target, systemic risk, delivery device, and formulation, general guidelines aiding inhaled drug design can be applied and are summarised in this review.


Assuntos
Aerossóis/farmacologia , Sistemas de Liberação de Medicamentos , Medicamentos para o Sistema Respiratório/farmacologia , Doenças Respiratórias/tratamento farmacológico , Administração por Inalação , Química Farmacêutica/métodos , Química Farmacêutica/tendências , Sistemas de Liberação de Medicamentos/instrumentação , Sistemas de Liberação de Medicamentos/métodos , Humanos
2.
Ann N Y Acad Sci ; 1280: 35-9, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23551101

RESUMO

Asthma and chronic obstructive pulmonary disease (COPD) are characterized in their pathogenesis by chronic inflammation in the airways. Phosphoinositide 3-kinase δ (PI3Kδ), a lipid kinase expressed predominantly in leukocytes, is thought to hold much promise as a therapeutic target for such inflammatory conditions. Of particular interest for the treatment of severe respiratory disease is the observation that inhibition of PI3Kδ may restore steroid effectiveness under conditions of oxidative stress. PI3Kδ inhibition may also prevent recruitment of inflammatory cells, including T lymphocytes and neutrophils, as well as the release of proinflammatory mediators, such as cytokines, chemokines, reactive oxygen species, and proteolytic enzymes. In addition, targeting the PI3Kδ pathway could reduce the incidence of pathogen-induced exacerbations by improving macrophage-mediated bacterial clearance. In this review, we discuss the potential and highlight the unknowns of targeting PI3Kδ for the treatment of respiratory disease, focusing on recent developments in the role of the PI3Kδ pathway in inflammatory cell types believed to be critical to the pathogenesis of COPD.


Assuntos
Asma/tratamento farmacológico , Inibidores de Fosfoinositídeo-3 Quinase , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Asma/enzimologia , Células Epiteliais/metabolismo , Humanos , Inflamação/metabolismo , Isoenzimas/antagonistas & inibidores , Isoenzimas/metabolismo , Macrófagos/metabolismo , Terapia de Alvo Molecular , Neutrófilos/metabolismo , Estresse Oxidativo , Fosfatidilinositol 3-Quinases/metabolismo , Doença Pulmonar Obstrutiva Crônica/enzimologia , Espécies Reativas de Oxigênio/metabolismo , Linfócitos T/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA